Chernett Jorey purchased $80K of STIM

Chernett Jorey purchased 40,000 shares of Neuronetics, Inc. (STIM) at $1.99 on 2026-11-09.

Original reporting
SEC EDGAR · Chernett Jorey
Published Nov 14, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 3:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Neutral
high confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMNeutralLow
01

Why it matters

The disclosed insider purchase is a primary filing but of modest size, offering limited actionable insight.

02

Market read

Minor insider buying; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical trial results could be the real driver of insider activity.

Relevance 4/10Novelty 4/10Timing: filing date 2026-11-13

Background

Neuronetics (STIM) is a medical device company focused on neurostimulation therapies.

Company-level read

Ticker impact

$STIMNeutralHigh confidence
Context

Form 4 shows insider Chernett Jorey bought 40,000 shares of Neuronetics for $79,600, increasing his stake to over 10% ownership.

Expected impact

likely modest upward pressure as market prices in insider confidence

Evidence & confidence

Purchase size is modest relative to market cap and typical daily volume; price effect expected to be minimal.

Market effects

None

None

None

Counterpoint

Insider purchase could be routine portfolio rebalancing, not a bullish signal.

Key entities

  • Chernett Jorey

    10% owner of Neuronetics who made the purchase.

  • Neuronetics, Inc.

    Issuer of the STIM ticker.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.